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Mutant cancer subpopulations have the potential to derail durable patient responses to molecularly targeted cancer
therapeutics, yet the prevalence and size of such subpopulations are largely unexplored. We employed the sensitive and
quantitative Allele-specific Competitive Blocker PCR approach to characterize mutant cancer subpopulations in ductal
carcinomas (DCs), examining five specific hotspot point mutations (PIK3CA H1047R, KRAS G12D, KRAS G12V, HRAS
G12D, and BRAF V600E). As an approach to aid interpretation of the DC results, the mutations were also quantified in
normal breast tissue. Overall, the mutations were prevalent in normal breast and DCs, with 9/9 DCs having measureable
levels of at least three of the fivemutations.HRASG12Dwas significantly increased inDCs as compared to normal breast.
Themost frequent pointmutation reported in DC byDNA sequencing, PIK3CAH1047R,was detected in all normal breast
tissue and DC samples and was present at remarkably high levels (mutant fractions of 1.1 × 10−3 to 4.6 × 10−2) in 4/10
normal breast samples. In normal breast tissue samples, PIK3CA mutation levels were positively correlated with age.
However, the PIK3CA H1047R mutant fraction distributions for normal breast tissues and DCs were similar. The results
suggest PIK3CAH1047Rmutant cells have a selective advantage in breast, contribute to breast cancer susceptibility, and
drive tumor progression during breast carcinogenesis, even when present as only a subpopulation of tumor cells.
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The advent of personalized medicine has created opportunities and
challenges with respect to how the measurement and understanding
of the underlying genetic lesions that cause cancer can be translated
into improved health outcomes. Specific cancer mutations can inform
cancer diagnosis and prognosis, and predict response to treatment
and/or development of resistance to particular therapies [1–6].
Molecularly targeted therapies directed against the bulk of a cancer
may create opportunities for the proliferation of minor subpopula-
tions of cancer cells lacking the target, leading to cancer recurrence/
progression and relapse. Knowledge regarding the prevalence and size
of low frequency cancer subpopulations has the potential to inform
the development of more efficacious and durable personalized cancer
therapies and/or treatment strategies. Therefore, it is important to
characterize cancer mutations using high-sensitivity methods, as a
complement to the relatively low-sensitivity cancer genome charac-
terizations that have been conducted [7–9].
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breast cancer development when mutated. DNA sequencing detects
mutations present at relatively high frequencies, although greater
sensitivity can be achieved using non-standard methods [10,11].
TP53 is the most frequently mutated gene in ductal carcinoma (DC,
see Table 1), with PIK3CA the second most mutated gene. The
PIK3CA gene encodes the p110α catalytic subunit of the class IA
isoform of a lipid kinase, designated PI3-kinase (PI3K) [12].
According to the COSMIC or TCGA database, mutation of
PIK3CA occurs in 22% (327/1551) or 24% of DCs, respectively
[7,8,13]. The PIK3CA gene exhibits three hotspots for point
mutation that encompass N90% of all reported PIK3CA mutations.
These mutations are localized in the helical and kinase domains of the
protein [14].
The PIK3CA H1047R mutation accounts for 56% of all PIK3CA
mutations detected in DCs [7]. Other cancer-associated hotspot
oncomutations have been reported in DCs, but no single base
substitution mutation is as prevalent in DCs as the PIK3CAH1047R
mutation (detected in 12% of DCs characterized by DNA
sequencing) [7]. The PIK3CA H1047R mutation causes an
overactivation of PI3K and enhances binding of PI3K to the cell
membrane, which results in oncogenic transformation, increased
cell proliferation, cell growth, survival, changes in gene expression,
and altered invasion potential [14–17]. In advanced cancers, the
PIK3CA H1047R mutation predicts increased partial response and
progression-free survival in patients treated with PI3K/AKT/mTOR
pathway inhibitors [16,18]. Conversely, the PIK3CA H1047R
mutation is associated with clinical resistance to the EGFR-inhibitor,
cetuximab [19].
RAS proteins play an important role in mammary signaling
pathways, including the MAPK, PI3K and JAK-STAT pathways.
These signaling pathways control important cellular functions,
including cell proliferation, differentiation, migration and apoptosis.
According to the COSMIC database [7], mutations in KRAS are
present in only 2% (13/700) of DCs. Nevertheless, low frequency
measurement of KRAS mutation in breast cancer is of interest,Table 1. Prevalence of gene mutations in ductal carcinomas of the breast.
Rank Gene Prevalence (%)
1 TP53 229/749 (31)
2 PIK3CA 321/1551 (21)
3 GATA3 10/52 (19)
4 BRCA1 13/90 (14)
5 ARID1A 9/78 (12)
6 APC 15/189 (8)
7 CASC5 3/45 (7)
8 NUP98 5/78 (6)
9 AKAP9 4/78 (5)
10 PTEN 13/256 (5)
11 AKT1 36/893 (4)
12 KIT 13/331 (4)
13 NOTCH1 5/113 (4)
14 MYH9 3/78 (4)
15 MLL3 3/78 (4)
16 CDH1 8/237 (3)
17 BRCA2 5/149 (3)
18 KRAS 13/700 (2)
19 EGFR 10/724 (1)
20 ERBB2 5/389 (1)
NR BRAF 0/522 (0)
NR HRAS 0/508 (0)
Data taken from the COSMIC database (www.cancer.sanger.ac.uk/cosmic), limited to ductal
carcinomas. NR; not reportedbecause minor KRAS mutant subpopulations (not detected by DNA
sequencing) exist and have been shown to cause therapeutic resistance
in other types of cancer [5,6]. Minor subpopulations of KRASmutant
cells (G12D and G12V), which exist in lung, thyroid, and colon
cancers, have been quantified using Allele-specific Competitive
Blocker PCR (ACB-PCR) [20–22]. Among PTCs, for example,
29% and 35% of cancers had mutant subpopulations of KRAS G12D
and G12V, respectively, at levels greater than the upper 95%
confidence interval of that present in normal thyroid, despite KRAS
mutations being reported in only ~2% of PTCs by DNA sequencing
[7]. DNA sequencing has detected KRAS G12D and G12V
mutations in 3% and 4% of lung adenocarcinomas, respectively,
but ACB-PCR demonstrated that 76% of the lung adenocarcinomas
had a KRAS G12D or G12V mutant fractions (MFs) greater than
the upper 95% confidence interval of that measured in normal
lung [20]. Similar findings of prevalent KRASmutant subpopulations
in colonic adenomas and/or carcinomas have been obtained using
ACB-PCR and other sensitive mutation detection methods [5,22].
In colorectal cancer (CRC) and non-small cell lung cancer (NSCLC),
pre-existing KRAS mutant subpopulations can abrogate response
to EGFR-targeted therapeutics (cetuximab, panitumimab, erlotinib,
and gefitinib) [3,4].
HRAS mutations are prevalent in salivary gland, urinary tract,
upper aerodigestive tract and cervical cancers (with HRAS mutant
frequencies of 15%, 11%, 9%, and 9%, respectively) [23]. However,
detection ofHRASmutations in breast cancers is rare (b1%) [23] and
0/508 DCs described in the COSMIC database carry HRAS
mutation [7]. Somatic point mutations in HRAS occur most
frequently at codons 12, 13 and 61 [7,23].
BRAF mutations are prevalent in malignant melanomas, PTCs,
non-Hodgkin lymphomas, CRCs, and NSCLCs, but BRAF
mutations have not been detected in DCs of the breast by DNA
sequencing (0/522, see Table 1) [7]. Somatic point mutations in
BRAF occur primarily in codon 600 of exon 15 and result in
constitutive activation of the mitogen-activated protein kinase
(MAPK) pathway. In fact, the BRAF V600E mutation (GTG to
GAG) accounts for N95% of all reported BRAF mutations and has
been associated with lack of response to therapies that target the
EGFR [2].
Although KRAS, HRAS and BRAF mutations are rarely, if ever,
detected in breast cancers by DNA sequencing, such mutations have
been found in breast cancer cell lines [24], suggesting that breast
cancers encompass minor KRAS, HRAS and BRAF mutant
subpopulations that can be expanded in culture. Therefore, such
mutations may be contributing to breast carcinogenesis in a manner
that cannot be assessed by sequencing cancer DNA.
ACB-PCR is an allele-specific PCR amplification method that can
quantify specific base substitution mutations when the mutation is
present at a level of at least three mutant copies per 300,000 wild-type
(WT) copies of a gene sequence (MFs of ≥10−5) in a given DNA
sample. ACB-PCR has been used to quantify levels of cancer driver
mutations in normal tissues and corresponding cancer samples in
order to elucidate the potential for spontaneous mutations in normal
tissues to drive tumor development, and evaluate the potential for
specific mutant cancer subpopulations to impact acquired resistance
to treatment, [20–22]. Here we apply this paradigm to normal breast
tissues and DCs of the breast, examining cancer driver mutations that
are either frequently detected in DCs or have been implicated in
responses to personalized cancer treatments in other cancer types.
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approach to quantify five different hotspot cancer-driver mutations
(PIK3CA H1047R, KRAS G12D, KRAS G12V, HRAS G12D, and
BRAF V600E) in 10 normal breast and 9 DC samples.
Materials and Methods
Sample Collection
Procedures for the acquisition and analysis of anonymous human
tissues were reviewed by the FDA Research Involving Human
Subjects Committee (RIHSC, FWA 00006196). The intent of the
study was to quantify mutations in normal breast and DCs. After
obtaining the PIK3CAH1047R results, however, a parallel analysis of
the same mutation in normal thyroid and papillary thyroid
carcinomas (PTCs) was deemed necessary. These tissues were selected
because PTCs carry PIK3CA mutation infrequently (2%) [7]. Ten
fresh-frozen normal breast samples and 20 normal thyroid samples
[21], collected at autopsy, were purchased from the National Disease
Research Interchange (NDRI; Philadelphia, PA). Tissue donors died
from causes unrelated to cancer or diseases affecting breast or thyroid.
Nine fresh-frozen primary breast DCs and 20 fresh-frozen PTCs [21]
were provided by the National Cancer Institute’s Cooperative
Human Tissue Network (CHTN). One PTC was purchased from
NDRI. All cancer specimens were histologically evaluated by board
certified pathologists, who confirmed the original diagnosis. One
additional sample that was analyzed was a tumor margin. This sample
was originally mislabeled as a DC, when in fact it was histologically
characterized as breast fat with necrosis.
DNA Isolation
DNA from normal thyroid and PTCs was isolated as described
previously [21]. Normal breast and breast DC tissue samples were
frozen in liquid nitrogen, pulverized, and then DNA was isolated as
described previously [21].
First-Round PCR
High-fidelity, first-round PCR amplicons encompassing human
PIK3CA codon 1047, KRAS codon 12, HRAS codon 12, and
BRAF codon 600 were performed using 1 μg of EcoRI-digested
normal breast or DC genomic DNA as template. PIK3CA first-round
PCR products, encompassing codon 1047, were generated using 1 μg
of EcoRI-digested genomic DNA from normal thyroid and PTCs.
For amplification of KRAS, HRAS, and BRAF, each 200 μl PCR
reaction of contained: 10 mM KCl, 10 mM (NH4)2SO4, 20 mM
Tris–HCl (pH 8.75), 2 mMMgSO4, 0.1% Triton X-100, 0.1 mg/ml
bovine serum albumin, 0.2 mM dNTPs, and 10 units of cloned
PfuUltra Hotstart DNA Polymerase (Agilent Technologies, Santa
Clara, CA). The conditions used for PIK3CA first-round PCR were
identical, except that 12.5 units of cloned PfuUltra Hotstart DNA
Polymerase were used. All PCR experiments were carried out using
DNA Engine or DNA Engine Tetrad thermocyclers (Bio-Rad,
Hercules, CA). Primer sequences and thermocycler reaction
conditions for each target are given in Supplementary Materials
(Table S1). Following preparative agarose gel electrophoresis,
PIK3CA, KRAS, and BRAF PCR products were isolated using a
Geneclean Spin Kit (MP Biomedicals, Solon, OH), and recovered in
TE buffer (5 mM Tris, 0.5 mM EDTA, pH 7.5). HRAS PCR
products were purified by ion-pair reverse phase chromatography
using a WAVE Nucleic Acid Fragment Analysis System (Transge-nomics Inc, Omaha, NE). PCR products were evaporated to dryness
and resuspended in TE buffer. All PCR products were frozen as
multiple single-use aliquots. The DNA concentrations of aliquots
were established by repeated measurement using an Epoch
Spectrophotometer (BioTek, Winooski, VT). The final DNA
concentration of each amplicon (PIK3CA, KRAS, HRAS, and
BRAF) was calculated from three determinations that varied by
≤10% from the group mean.
ACB-PCR
ACB-PCR is an allele-specific amplification method that: 1) relies
upon parallel a set of mutant fraction (MF) standards analyzed in
parallel with first-round PCR products generated from unknown
samples (comparing equal numbers of molecules), and 2) can be used to
selectively amplify and quantify a mutant allele in a 100,000-fold excess
of WT allele. KRAS G12D (codon 12 GAT) and G12V (codon 12
GTT) mutant and KRAS WT (codon 12 GGT) standards were
prepared by digestion of cloned mutant or WT plasmid DNAs with
AflII and AvaII and isolation of a DNA segment identical in sequence
composition to the first-round PCR product prepared from isolated
breast DNA samples. Mutant PIK3CA H1047R (codon 1047 CGT),
HRAS G12D (codon 12 GAC), and BRAF V600E (codon 600
GAG) andWT standards (PIK3CA codon 1047CAT,HRAS codon 12
GGC, and BRAF codon 600 GTG) were prepared by PCR
amplification of cloned mutant or WT plasmid DNAs, using the
same primers and conditions used for amplification of the target
sequence from genomic DNAs (see Table S1). Purification of PIK3CA
and BRAF WT, mutant, and unknown PCR products was performed
using preparative agarose gel electrophoresis as described above.
Purification of HRAS mutant, WT and unknown PCR products was
accomplished by ion-pair reverse phase chromatography using a
Transgenomic WAVE Nucleic Acid Fragment Analysis System.
For each ACB-PCR assay, purified PIK3CA, KRAS, HRAS, or
BRAF mutant and WT reference DNAs were mixed to generate
standards with MFs of 10−1, 10−2, 10−3, 10−4, 10−5, and 0
(containing only the WT sequence), at a concentration of 5 × 107
copies/μl for the PIK3CA, KRAS, and BRAF standards, and 108
copies/μl for the HRAS standards. Each ACB-PCR reaction
incorporated 10 μl of each DNA mixture, for a total of 5 × 108
copies per reaction for PIK3CA, KRAS, and BRAF assays, and 109
copies per reaction for HRAS. Each MF standard was analyzed in
duplicate, along with a no-DNA control. The ACB-PCR was
performed in a 96-well PCR plate (Thermo Fisher Scientific,
Waltham, MA). The ACB-PCR primer sequences and thermocycler
reaction conditions used for each target are given in Supplementary
Material (Table S2).
QClamp XNA-PCR
QClamp XNA-PCR is a real-time PCR technology that utilizes a
sequence specific oligonucleotide blocker that has a modified
backbone chemistry. The use of a modified backbone increases the
binding affinity and hence the melting temperature (Tm) of the
blocking oligomer which leads to more efficient clamping of WT
alleles [25]. The binding of sequence specific XNA oligomers is
independent of salt concentration as the backbone has no ionic
charge. The XNA-PCR reaction conditions used in the quantification
of the PIK3CA H1047R mutation were 95°C for 300 seconds,
followed by 40 cycles of 95°C for 20 seconds, 70°C for 20 seconds,
and 60°C for 60 seconds.
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and Data Collection
Equal volumes of ACB-PCR products were analyzed on
non-denaturing 8% polyacrylamide gels, loading 10 μl of KRAS
and BRAF ACB-PCR products or 15 μl of the PIK3CA and HRAS
ACB-PCR products. The fluorescent ACB-PCR products were
visualized using a PharosFX Molecular Imager with an external blue
laser (Bio-Rad). Pixel intensities of the correct-sized bands were
quantified using Quantity One software and a locally-averaged
background correction (Bio-Rad). Although duplicate 10−1 to 10−5
MF standards were included in each experiment, the set of standards
that gave the best quantification across the observable range of MFs
for an entire set of unknown samples was used to construct each
standard curve [10−5 to 10−1 for PIK3CA and BRAF, 10−5 to 10−3
for KRAS and HRAS]. For PIK3CA and KRAS, log-log plots relating
MF to fluorescence (in pixels) were constructed and fit with a
power function. For BRAF, log-linear plots relating MF to
fluorescence were constructed and fit with a logarithmic function.
For HRAS, linear-linear plots relating MF to fluorescence were
constructed and fit with a linear function. Using the function of the
standard curve and the pixel intensities of the ACB-PCR products for
each mutation, the MF of each mutation within each unknown
sample was calculated.
Statistical Analyses
For each sample/target, MF was calculated as the arithmetic
average of three independent MF measurements. Calculated MFs less
than the smallest ACB-PCRMF standard employed (MF of 10−5) are
reported as non-detects (ND) in Table 2. The average MF
measurement for each sample was log10-transformed. For each
mutational target, the geometric mean MF was calculated as the
average log10-transformed MFs measured in a particular tissue type
(breast, thyroid, DC, or PTC). Log10-transformed data were used for
statistical analyses. Because not all log-transformed data were
normally distributed, non-parametric analyses (Mann–WhitneyTable 2. Individual MF measurements of five hotspot cancer driver mutations in normal breast and
ID Age/Race PIK3CA H1047R
MF
Normal Breast 1 83/C 4.59 × 10−2
2 87/C 1.07 × 10−2
3 60/C 1.93 × 10−2
4 63/C 1.06 × 10−2
5 68/C 1.95 × 10−4
6 67/C 1.03 × 10−3
7 49/C 1.25 × 10−5
8 43/AA 4.14 × 10−5
9 29/AA 4.76 × 10−5
10 23/AA 1.69 × 10−4
*Geomean 7.80 × 10−4
Ductal Carcinomas 1 40/AA 2.97 × 10−2
2 45/AsA 1.57 × 10−5
3 47/C 4.37 × 10−2
4 50/C 1.24 × 10−2
5 60/C 1.84 × 4−4
6 42/C 9.26 × 10−5
7 60/C 1.18 × 10−2
8 62/C 3.86 × 10−4
9 38/C 7.24 × 10−5
*Geomean 1.04 × 10−3
*Group geomeans were estimated using individual MFs calculated from ACB-PCR pixel intensities arank sum test or Fisher’s exact test) were employed to identify
significant differences between MFs in normal tissue and cancer
tissue. The Mann–Whitney rank sum test was used when a
quantitative ranking of MFs was possible (breast PIK3CA H1047R,
KRAS G12D, and HRAS G12D). Fisher’s exact test was used when
datasets contained multiple samples below the levels of accurate
ACB-PCR quantification (10−5), and compared the numbers of
samples with MFs N10−5 and b10−5 in normal and cancer tissue
(breast KRAS G12D, breast BRAF V600E, and thyroid PIK3CA
H1047R). Pearson correlation coefficients, between donor age and
MF, were determined using normally-distributed, log-transformed
data and considering only samples with measureable MFs (N10−5).
Two-tailed p-values of less than 0.05 were considered significant. All
statistical analyses were performed using GraphPad Prism 5 Software
(GraphPad Software, Inc., La Jolla, CA).
Results
To elucidate the role of hotspot cancer driver mutations in breast
carcinogenesis, quantitative profiles of several such mutations were
generated for normal breast and DCs using ACB-PCR. The
mutational targets included: 1) the most frequently reported point
mutation in DCs (PIK3CA H1047R), 2) mutations that have been
reported rarely in DCs, but are present as subpopulations in other
cancer types (KRAS G12D and KRAS G12V), and 3) mutations that
have not been observed in DCs (HRAS G12D and BRAF V600E).
The levels of these mutations were measured in ten normal breast
tissues, nine DCs and one fat sample with necrosis (associated with a
DC). The PIK3CA H1047R, KRAS G12D, KRAS G12V, HRAS
G12D, and BRAF V600E MF measurements of the twenty samples
generated a dataset of 299 individual ACB-PCR measurements. Each
unknown was quantified in three independent experiments (except
sample #2, with only 2 KRAS G12D measurements). The average
coefficient of variation for the triplicate PIK3CA H1047R, KRAS
G12D, KRAS G12V, HRAS G12D and BRAF V600E MF









4.66 × 10−5 5.66 × 10−5 1.43 × 10−4 ND
7.88 × 10−5 1.63 × 10−5 1.17 × 10−4 ND
8.27 × 10−5 7.40 × 10−6 1.10 × 10−4 ND
1.73 × 10−4 4.06 × 10−5 8.40 × 10−5 ND
1.29 × 10−4 1.98 × 10−5 2.91 × 10−6 ND
9.78 × 10−5 1.25 × 10−5 2.23 × 10−4 ND
1.45 × 10−4 1.01 × 10−5 5.28 × 10−5 ND
2.50 × 10−5 ND 1.78 × 10−4 ND
2.98 × 10−5 ND 3.37 × 10−5 ND
4.75 × 10−5 ND 8.15 × 10−5 1.74 × 10−4
7.13 × 10−5 1.23 × 10−5 6.94 × 10−5 2.02 × 10−6
2.87 × 10−5 3.81 × 10−5 3.16 × 10−4 ND
2.21 × 10−5 ND 2.71 × 10−4 ND
4.86 × 10−5 ND 3.58 × 10−4 ND
4.81 × 10−5 ND 3.83 × 10−4 ND
3.54 × 10−5 1.13 × 10−5 1.38 × 10−4 ND
2.16 × 10−4 1.33 × 10−5 1.93 × 10−4 ND
3.55 × 10−5 2.58 × 10−5 1.90 × 10−4 ND
8.99 × 10−5 2.31 × 10−5 1.54 × 10−4 2.28 × 10−4
8.63 × 10−5 1.70 × 10−5 1.77 × 10−4 3.27 × 10−4
5.27 × 10−5 1.37 × 10−5 2.27 × 10−4 6.49 × 10−6
nd standard curves, even when measured MFs were below 10−5 (noted as non-detects, ND).
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target are provided in Supplementary Material (Figure S1). Following
ACB-PCR, MF quantification was achieved by interpolation of
fluorescent intensities of unknown samples with that of a standard
curve constructed using samples with defined ratios of mutant:WT
alleles (i.e., duplicate 10−1, 10-2, 10−3, 10−4, 10−5 and 0 standards).
A representative example of a standard curve used for each mutational
target is shown in Supplementary Material (Figure S2). For the
PIK3CA H1047R MF measurements, the average coefficient of
determination (r2) for the standard curves was 0.9459 (range 0.9346
to 0.9586). For the KRAS GAT MF measurements, the average r2
for the standard curves was 0.9936 (range 0.9876 to 0.9965). For
the KRAS GTT MF measurements, the average r2 for the
standard curves was 0.9945 (range 0.9905 to 0.9973). For the
HRAS G12D MF measurements, the average r2 for the standard
curves was 0.9809 (range 0.967 to 0.9914). For the BRAF V600E
MF measurements, the average r2 for the standard curves was 0.9939
(range 0.9869 to 0.9953).
MF Measurements in Normal Breast
The normal breast samples were derived from ten women, 23–87
years of age (57.20 ± 21.19, mean years of age ± SD), which included
seven Caucasian and three African American women. The average
ACB-PCRMF measurement for each target mutation in each normal
breast sample is given in Table 2. For PIK3CA H1047R and KRAS
G12D, 10/10 (100%) of normal breast samples had measureable
levels of mutation (i.e., N10-5, the lowest standard employed, see
Figure 1, A and B). For HRAS G12D, KRAS G12V, and BRAFFigure 1. Frequency distributions of individual MF measurements in
(C), HRAS G12D (D), and BRAF V600E (E). Individual measurements ar
50th, 75th, and 95th percentiles for each population distribution of M
below the limit of accurate ACB-PCR quantification. The * indicates a
normal breast (two-tailed, Mann–Whitney rank sum test; P = .0033).V600E, 9/10 (90%), 6/10 (60%), and 1/10 (10%) of normal breast
samples had measureable levels of mutation (see Figure 1C, 1D, and
1E), respectively. The PIK3CA H1047R, KRAS G12D, KRAS
G12V, HRAS G12D, and BRAF V600E geometric mean MFs for
normal breast were 7.80 × 10−4, 7.13 × 10−5, 1.23 × 10−5, 6.94 ×
10−5, and 2.02 × 10−6, respectively (Table 2). A linear regression
analysis, describing the relationship between age and PIK3CA
H1047R MF in normal breast, is shown in Figure 2. There is a
positive correlation between tissue donor age and PIK3CA H1047R
MF (Pearson r = 0.7130, P = .0206). No significant correlation was
observed between the age of the tissue donor and KRAS G12D,
KRAS G12V, or HRAS G12D MF in normal breast tissue (there
were too few normal breast samples with BRAF V600E MFs N10−5
to perform a correlation analysis).
Given the remarkably high levels of PIK3CA H1047R mutation
detected in 4/10 normal breast tissue samples, a second sensitive
mutation detection method was employed to confirm the ACB-PCR
results. The QClamp™ Gene Mutation Test (DiaCarta, Inc.,
Richmond, CA) is an allele-specific PCR method that employs a
xenonucleic acid "clamp" to suppress amplification of WT sequence.
The QClamp method can detect mutations when present in a DNA
samples at a level of 0.05% (MF = 5 × 10−4, see Supplementary
Material, Table S3 and Figure S3). This is consistent with the
observation that the QClamp™ method did not detect PIK3CA
H1047R mutation in samples that had ACB-PCR MFs less than 5 ×
10−4 (see the comparison on MF measurements obtained using
QClamp™ and ACB-PCR, provided in Supplementary Material,
Table S4). The QClamp™ and PIK3CA MF measurements werenormal breast and DCs for PIK3CA (A), KRAS G12D (B), KRAS G12V
e plotted along with box and whisker plots indicating the 5th, 25th,
F measurements. Measurements in the shaded areas (b10−5) are
significant difference in HRAS G12D MFs in DCs as compared to
Figure 2. Linear regression between normal breast tissue donor
age and PIK3CA H1047R MF. Dashed lines describe the 95%
confidence interval.
Figure 3. The co-occurrence of PIK3CA H1047R, KRAS G12D, KRAS
G12V, HRAS G12D, and BRAF V600E mutation within individual
samples. The average ACB-PCR MF measurements collected on
ten normal breast samples are shown in (A). The average ACB-PCR
MF measurements collected on nine DCs and one breast fat
sample associated with a DC are shown in (B). Error bars denote
the standard error of the mean. Measurements in the shaded areas
(b10−5) are below the limit of accurate ACB-PCR quantification.
258 Breast Cancer Heterogeneity and PIK3CA, KRAS, HRAS, and BRAF Mutations Myers et al. Neoplasia Vol. 18, No. 4, 2016generally in good agreement for normal breast samples with PIK3CA
H1047R MFs greater than 10-3. Regarding the four samples that had
measureable mutation using both methods, the ACB-PCR measure-
ments were 2.2- to 3.3-fold greater than the corresponding QClamp™
measurements (see Supplementary Material, Table S4). The
ACB-PCR assay may be overestimating the PIK3CA MF somewhat,
given that the ACB-PCR standard curves used to calculate PIK3CA
H1047R MF covered a range of five orders of magnitude and had
lower coefficients of determination than the QClamp™ standard curve
(r2 = 0.9459, on average, for three replicate ACB-PCR assays vs r2 =
0.9983 for the QClamp™ assay). Nevertheless, the QClamp™ analysis
confirmed that there are remarkably high levels of PIK3CA mutation
in 4/10 (40%) of the normal breast tissue samples (QClamp™ MF
levels between 3.7 × 10−3 and 2.1 × 10−2). These measurements
suggest that 4/10 normal breast tissue samples carry one PIK3CA
H1047R mutant cell per every 24 to 135 PIK3CA WT cells.
MF Measurements in DCs
DCs were derived from nine women, 38–65 years in age (49.33 ±
9.23, mean years in age ± SD), including eight Caucasians, one
African American, and one Asian American. The patient and tumor
characteristics for the nine DCs are given in Supplementary Material
(see Table S5). The average ACB-PCR measurement for each
mutation in each DC sample is given in Table 2. All nine DCs had
measurable levels (≥10−5) of PIK3CA H1047R, KRAS G12D, and
HRAS G12D mutations (see Figure 1A, B, and D). For KRAS G12V
and BRAF V600E, 6/9 and 2/9 DCs had MFs greater than the lowest
standard employed (10−5, see Figure 1, C and E). The PIK3CA
H1047R, KRAS G12D, KRAS G12V, HRAS G12D, and BRAF
V600E geometric mean MFs for the DCs were 1.04 × 10−3, 5.27 ×
10−5, 1.37 × 10−5, 2.27 × 10−4, and 6.49 × 10−6, respectively (see
Table 2). A comparison of the frequency distributions for PIK3CA
H1047R, KRAS G12D, KRAS G12V, HRAS G12D, and BRAF
V600E MFs in normal breast and DCs is shown in Figure 1. HRAS
G12D MFs were significantly greater in DCs as compared to normal
breast (two-tailed, Mann-Whitney rank sum test; P = .0033). No
significant differences in MF were observed between normal breast
and DCs for PIK3CA H1047R, KRAS G12D, KRAS G12V, or
BRAF V600E.Co-Occurrence of PIK3CA H1047R, KRAS G12D and G12V,
HRAS G12D, and BRAF V600E Mutations in Normal Breast
and DCs
The mean MF measurements for the five different hotspot point
mutations (PIK3CA H1047R, KRAS G12D and G12V, HRAS
G12D, and BRAF V600E) within individual samples are plotted in
Figure 3A for normal breast and Figure 3B for DCs and the breast fat
sample. All normal breast and DCs contained measureable levels of
three or more cancer driver point mutations (at levels ≥10−5). For
normal breast, 7/10 (70%) of samples had four mutations, and 3/10
(30%) of samples had three mutations at levels ≥10−5. For DCs, 6/9
(67%) of samples had four mutations, while 3/9 (33%) of samples
had three mutations at levels ≥10−5. Table 3 describes the
co-occurrence of hotspot point mutations in the DCs. For example,
Table 3 shows that 9/9 (100%) of DCs carry PIK3CA H1047R,
KRAS G12D, and HRAS G12D mutations.











PIK3CA H1047R - 100% 66.67% 100% 22.22%
KRAS G12D - 66.67% 100% 22.22%
KRAS G12V - 66.67% 22.22%
HRAS G12D - 22.22%
BRAF V600E -
Figure 4. ACB-PCR analysis of normal thyroid tissue and papillary
thryoid carcinomas. Individual measurements and box and whisker
plots indicating the 5th, 25th, 50th, 75th, and 95th percentiles of
the population distribution of PIK3CA H1047R MF measurements
in normal thyroid and PTCs are presented in (A). Measurements in
the shaded areas (b10−5) are below the limit of accurate ACB-PCR
quantification. The * indicates a significant difference in distribu-
tion of PIK3CA H1047R MFs greater than or less than 10−5 was
observed between PTCs and normal thyroid samples (Fisher’s
exact test; P = .0095). Linear regression analysis depicts the
relationship between normal thyroid tissue donor age and PIK3CA
H1047R MF (B). MF measurements below the limit of accurate
ACB-PCR quantification were not included in the linear regression
analysis shown. No significant correlation with age was observed
with or without including MFs b10−5. Dashed lines describe the
95% confidence interval.
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and PTCs
Our analyses identified 4/10 normal breast samples as having large
subpopulations of PIK3CA H1047R mutant cells. However, we
observed only a minor shift in the population distribution and
geometric mean MF between normal breast and DCs (Figure 1). In
order to clarify the significance of this result, we compared the
ACB-PCR results obtained in breast, where the PIK3CA H1047R
mutation is an established cancer driver mutation, to results obtained
from thyroid, where there is no evidence that the PIK3CA H1047R
mutation acts as a cancer driver mutation. Specifically, we measured
PIK3CA H1047R MF in 20 normal thyroid and 20 PTCs, a cancer
type with an exceedingly low reported frequency of PIK3CAH1047R
mutation detection [2/1120; 0.18%]. The clinical and pathological
information regarding the normal thyroid and PTC samples was
reported previously [21]. The PIK3CA H1047R geometric mean
MFs for normal thyroid and PTCs were 4.32 × 10−5 and 1.12 × 10−5,
respectively. For normal thyroid, 16/20 samples had detectable
levels of the PIK3CA H1047R mutation. For PTCs, 7/20 samples
had detectable levels of PIK3CA H1047R mutation. This is in
contrast to breast, where all samples had measureable levels of the
PIK3CA H1047R mutation. Furthermore, a significant decrease
in PIK3CA H1047R mutation was observed in PTCs, as compared
to normal thyroid (see Figure 4A). No significant correlation was
observed between age and PIK3CA H1047R MF in normal thyroid
(Pearson r = 0.2898, P = .2762; Figure 4B), unlike breast, where a
significant positive correlation between age and PIK3CA H1047R
MF was observed.
Discussion
The discovery that mutant cancer subpopulations limit patient
responses to molecularly targeted, personalized cancer therapies has
created an urgent public health need for knowledge regarding the
prevalence and functional significance of such subpopulations
(reviewed in [3,4]). To address this knowledge gap, and develop a
new perspective on breast cancer heterogeneity, we performed
sensitive and quantitative analyses of specific cancer driver mutations.
This study focused on the measurement of the single most prevalent
base substitution mutation reported in DCs (PIK3CAH1047R), two
mutations rarely detected in DCs by DNA sequencing (HRAS G12D
and BRAF V600E), and two mutations implicated in the
development of acquired resistance to EGFR-targeted therapies
(KRAS G12D and KRAS G12V). The mutant proteins encoded by
these five activated oncogenes are attractive drug targets because of
their prevalence across multiple cancer types. Knowledge regarding
the fractions of cells carrying these mutations should inform the
development of strategies to treat DCs.
The results of our DC analyses are qualitatively similar and
consistent with published results, in that only the PIK3CA H1047R
mutation was prevalent at levels detectable by DNA sequencing[7,10,26,27]. Beyond that, the results of this study extend current
understanding of breast cancer heterogeneity in several ways.
First, three of the five mutations analyzed were present at measureable
levels in each DC analyzed, which is indicative of a remarkable level
of tumor heterogeneity. Second, the PIK3CA mutation was present
at some level in each of the DCs analyzed. And third, the low level
of HRAS G12D mutation measured in DCs (geometric mean
MF 2.27 × 10-4) was significantly greater than that present in
normal breast.
The therapeutic impact of PIK3CA mutation is an active area
of investigation [18]. The prevalence of PIK3CA mutation in DCs
is important because it has been reported to decrease time to
progression in the context of trastuzumab treatment of HER2-
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breast cancer studies found that patients with PIK3CA mutant breast
cancers had decreased relapse-free survival compared to patients with
PIK3CA WT cancers, although this difference was seen only when
trastuzumab was given in the neoadjuvant setting [29]. Recently, it
has been suggested that PIK3CA mutations play different roles in
early versus late ER-positive breast cancer [30]. In early breast cancer,
PIK3CA mutation may be a marker of hormone dependence and
good prognosis. In late/advanced breast cancers, it may contribute to
anti-estrogen resistance. For such cancers, patients may benefit from
combination treatment with an anti-estrogen and everolimus, an
inhibitor of TORC1 (downstream in the PI3K/AKT pathway) [30].
Given the prevalence of the mutant PIK3CA in breast and other
cancer types, targeting the mutant form of the protein is a viable
therapeutic approach. Work is underway to characterize the protein
binding pockets, in order to identify specific inhibitors of mutant
PIK3CA, including the H1047R mutant protein [14,31]. Our
observations indicate, however, that PIK3CA mutant DCs also carry
KRAS G12D and HRAS G12D mutations, suggesting that ultimately
there may be too many different subpopulations of driver mutations
in advanced cancers to target individually.
This study employed the paradigm of comparing mutation levels in
normal and cancer tissue, as a means of assessing the functional
significance of the mutant subpopulations. This was based on the
assumption that an increase in cancer MF (relative to normal) would
indicate that the mutation provided a positive selective advantage
during tumor progression. ACB-PCR has been used to show
significant increases in KRAS G12D or KRAS G12V mutation in
colon, lung, and thyroid tumors as compared to normal tissues
[20–22]. However, no significant differences in KRAS G12D and
KRAS G12V MF were observed between DCs and normal breast.
Regarding BRAF V600E mutation, only two of nine DCs and one of
ten normal breast samples had measureable levels of the mutation. A
small, but significant increase in HRAS G12D mutation was detected
in DC’s compared to normal breast (2.27 × 10−4 versus 6.94 × 10-5,
respectively). These results suggest that the HRAS G12D mutation is
playing a more significant role in breast cancer development than
previously recognized. Of interest in this regard is a study by Cha
et al.[32], which demonstrated that N-nitroso-N-methylurea-induced
rat mammary tumors arose from spontaneous Hras G12D mutant
cells of the mammary epithelium. The presence of HRAS and KRAS
mutation, albeit at low frequencies, in human DCs should be
considered carefully as investigators explore the potential use of
EGFR inhibitors for the treatment of breast cancer [33,34].
The most striking observation of the current study was that all
normal breast tissue samples had measureable levels of PIK3CA
H1047R mutation, some at remarkably high levels. To our
knowledge, there is only one previous report describing the detection
of PIK3CA mutant cells in normal breast (samples that subsequent
histopathological analysis identified as having columnar cell changes
or metaplasia) [35]. The observation that the most prevalent point
mutation identified in breast cancer is present at remarkably high
levels in normal breast lends credence to the idea that mutant PI3K
inhibitors might be used to prevent the development of breast cancer.
But, assuming that levels of PIK3CAmutation in normal breast DNA
could identify individuals at risk for developing breast cancer, it is
unlikely that this could be used as a screening tool in healthy women.
For this reason, there is considerable interest in analyzing liquid
biopsies, even though the tissue origin of the marker(s) may not bereadily known. For breast, however, DNA isolated from breast milk
might be a viable, non-invasive approach for exploring the use of
PIK3CAH1047R mutation as a quantitative biomarker of a woman’s
risk for developing breast cancer. This could be investigated first in
women who have a family history of breast cancer, especially in
families where the PIK3CA H1047R mutation was established as a
driver of breast cancer.
We have been using ACB-PCR quantification as a means to
investigate the tissue-specific “properties” of cancer driver mutations.
For example, past analyses have identified both positive and negative
selection of KRAS G12V mutation in colon and thyroid cancers. The
positive selection was established by mutant enrichment in colonic
adenomas or PTCs compared to normal [21,22]. The negative
selection was established by an inverse correlation between MF and
maximum tumor dimension for both tumor types, and a decrease in
MF during adenoma to carcinoma progression for CRC [3,22]. The
results of the current study allow us, for the first time, to characterize
the selective advantage provided by a specific mutation in the context
of normal breast. Specifically, linear regression analysis of PIK3CA
H1047RMF in breast tissue from donors of different ages leads to the
interpretation that the PIK3CA H1047R mutation increases as an
exponential function in normal breast, with an ~10% increase in MF
per year of age (Figure 2).
This study employed a comparison between breast and thyroid as
evidence to support the hypothesis that subpopulations of PIK3CA
H1047R mutation in normal breast drive the development of DC.
Evidence suggests that the PIK3CA H1047R mutation is not a driver
of papillary thyroid carcinogenesis. It is rarely detected in PTCs and
there was no significant increase in MF with age for normal thyroid.
While the PIK3CA H1047R mutation is present at relatively low
levels in normal thyroid, it decreases significantly in PTCs. This is
consistent with clonal expansion of non-PIK3CA mutant cells
diluting out the low spontaneous level of PIK3CA mutant cells in
thyroid. In contrast, remarkably high levels of PIK3CA H1047R are
present in normal breast samples and these levels are maintained (as
subpopulations) during progression to DCs. This supports the
interpretation that the mutation provides a selective advantage to the
developing tumor in the breast, but as a subpopulation.
A model depicting three possible pathways by which PIK3CA
mutant subpopulations could contribute to the development of DCs
is presented in Figure 5. Figure 5 is not intended to represent all
possible mutations that can occur, nor capture the full extent of the
co-occurrence of the multiple mutations that may exist as
subpopulations. Figure 5, A and B depict the development of a
PIK3CA H1047R mutant cancer from a single cell. According to
Figure 5A, the DC develops from a PIK3CA mutant cell, in which
case the mutation is present in all the malignant cells of the cancer.
Presumably, this contributes to the fraction of PIK3CA mutant DCs
that are detected by DNA sequencing. Figure 5B depicts the
occurrence of PIK3CA mutation as a secondary event, thereby
explaining its occurrence as a subpopulation. Figure 5C depicts tumor
initiation as a polyclonal interaction between PIK3CA mutant and
other mutant or epigenetically altered cells. Figure 5C incorporates
the idea that PIK3CA mutant subpopulations provide a functional
phenotype in trans that is necessary for the development of a
predominant clone.
Several lines of evidence support the carcinogenic pathway
depicted in Figure 5C. First, the frequency of PIK3CA mutation
detection in DCs is lower than that detected in breast hyperplasia,
Figure 5. Alternate pathways to PIK3CA-induced DC. DCs could be initiated from a PIK3CA mutant cell, generating a cancer where the
PIK3CA mutant cells predominate and the mutation would be detected by DNA sequencing (A). DCs could be initiated by a non-PIK3CA
mutant cell, with PIK3CA mutation arising as a secondary event (B). DC could be initatiated through the interaction of PIK3CA and
non-PIK3CAmutant clones with subsequent accumulation of mutation in both clonal populations (C). Pathways B and C have the potential
to generate minor mutant subpopulations that could be detected by ACB-PCR, but not DNA sequencing.
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found PIK3CA point mutations were detected in 31/62 (50%) of
proliferative lesions (usual ductal hyperplasia and columnar cell
change), with the PIK3CA H1047R mutation observed in 14/31
(45%) of the usual ductal hyperplasia samples. The same study found
PIK3CA H1047R mutation in 13/37 (35%) of invasive carcinomas
[27]. This is consistent with Figure 5C, which depicts PIK3CA
H1047R as a marker of susceptibility and an early driver of DC,
which may be outgrown by other transformed clones in the fully
developed cancer. Conversely, the more frequent detection of
PIK3CA mutation in hyperplasia than in DC cannot be explained
easily by the pathways depicted in Figure 5A or B, unless one assumes
PIK3CA mutant breast hyperplasia does not contribute to DC.
Several studies provide direct evidence of clonal cooperation
driving the development of tumor heterogeneity in mammalian
systems. Using a xenograft model to reproduce a frequent pattern of
EGFR heterogeneity in human glioblastomas, Inda et al. [36]
demonstrated that that a minor, EGFR mutant subclone could drivethe growth of a predominant, EGFR WT clone via a cytokine-
mediated mechanism. Subsequently, Marusyk et al.[37] demonstrat-
ed that cooperation between populations of clones (constructed by
lentivirus infection of a breast cancer cell line) can generate a
tumor-promoting microenvironment that stimulates tumor growth,
with driver subclones retained as minor subpopulations. By
investigating how a subpopulation of cells carrying an Hras oncogene
behaves when present with the parental cells (recapitulates a
monoclonal tumor origin) versus when present with other mutant
subclones, Cleary et al.[38] provided evidence of inter-clonal
cooperation between the WNT1 producing luminal cells and
mutant Hras expressing basal cells. Further support for the idea
that activated oncogenes drive tumor progression “in trans” via a
secretory mechanism comes from a study by Hobor et al.[39]. They
showed that colorectal cells sensitive to EGFR blockade can grow in
the presence of cetuximab when co-cultured with resistant cells or
with conditioned media from resistant cells, due to a mechanism
involving secretion of TGFα and amphiregulin. Therefore, some
262 Breast Cancer Heterogeneity and PIK3CA, KRAS, HRAS, and BRAF Mutations Myers et al. Neoplasia Vol. 18, No. 4, 2016activated oncogenes frequently found as cancer subpopulations may
have capabilities as “transdriver mutations,” meaning they drive
progression of a predominant clone through paracrine mechanisms.
Intratumoral heterogeneity and cooperativity between tumor sub-
populations has been demonstrated in a Trp53-null mouse model of
human breast cancer [40].
Some investigators have reached the conclusion that breast cancers
can be polyclonal in origin [41]. However, the “lasting paradigm” that
cancer is a disease of clonal growth that develops from a normal
precursor cell is a concept still held strongly by many [42]. In fact, a
recent cancer textbook concludes that there “is a widespread
consensus that the vast majority of advanced human tumors are
monoclonal growths descended from single normal progenitor cells
that took the first small steps to becoming cancerous” [43]. However,
adherence to the theory of monoclonal tumor origin has been
questioned [44]. This controversy is clearly related to the technical
difficulty associated with assessing the earliest events in carcinogen-
esis. Nevertheless, quantification of cancer driver mutations in normal
breast and DCs supports the interpretation that PIK3CA H1047R
mutation is a major driver of polyclonal DC initiation. Observations
from the literature, in conjunction with the data reported here,
suggest that: 1) spontaneous cancer driver mutations are not rare, 2)
cancer initiation often involves cooperative clonal interactions, and 3)
mutations that frequently appear as cancer subpopulations may
represent a class of “transdriver oncogenes.”
Conclusions
Hotspot cancer driver mutations PIK3CA H1047R, KRAS G12D,
HRASG12D, and to a lesser extent KRASG12V are present in normal
breast tissue. The PIK3CAH1047R mutation is present at remarkably
high levels in some normal breast tissue samples and the levels of this
mutation increase with age. This suggests PIK3CA H1047R mutation
may be a biomarker of breast cancer susceptibility and could be a
therapeutic target for breast cancer prevention. Subpopulations of
PIK3CA H1047R, KRAS G12D, KRAS G12V, and HRAS G12D are
prevalent in DCs, with 9/9 (100%) of DCs carrying at least three of
these mutations. Only the HRAS G12D mutation, however, was
present at a significantly greater level in DC than in normal breast. This
study illustrates how high-sensitivity quantification of cancer driver
mutations can complement data from large-scale cancer genome
sequencing to elucidate the role of cancer driver mutations in
carcinogenesis and to guide strategies for therapeutic intervention.
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